{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% confidence interval was not reached due to insufficient events being observed at the time of the analysis.","groupId":"OG000","lowerLimit":"2.3","upperLimit":"NA","value":"7.0"},{"comment":"Upper limit of 95% confidence interval was not reached due to insufficient events being observed at the time of the analysis.","groupId":"OG001","lowerLimit":"1.8","upperLimit":"NA","value":"6.4"},{"comment":"95% confidence interval was not reached due to insufficient events being observed at the time of the analysis.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"4.9"},{"comment":"Upper limit of 95% confidence interval was not reached due to insufficient events being observed at the time of the analysis.","groupId":"OG003","lowerLimit":"1.7","upperLimit":"NA","value":"7.1"},{"comment":"Upper limit of 95% confidence interval was not reached due to insufficient events being observed at the time of the analysis.","groupId":"OG004","lowerLimit":"2.8","upperLimit":"NA","value":"4.7"},{"comment":"95% confidence interval was not reached due to insufficient events being observed at the time of the analysis.","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"6.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"7"}],"units":"Participants"}],"description":"Overall survival was defined as the number of days from date of first study drug administration to death due to any cause. If a subject was not known to have died, then OS was censored, and the censoring date was the latest date the subject was known to be alive (on or before the cut-off date). The OS was estimated using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 0.1 mg/kg of GEN1029 every 2 weeks (Q2W) until the end of treatment.","id":"OG000","title":"Biweekly Regimen (GEN1029 0.1 mg/kg)"},{"description":"Participants received 0.2 mg/kg of GEN1029 Q2W until the end of treatment.","id":"OG001","title":"Biweekly Regimen (GEN1029 0.2 mg/kg)"},{"description":"Participants received 0.3 mg/kg of GEN1029 Q2W until the end of treatment.","id":"OG002","title":"Biweekly Regimen (GEN1029 0.3 mg/kg)"},{"description":"Participants received 1.0 mg/kg of GEN1029 Q2W until the end of treatment.","id":"OG003","title":"Biweekly Regimen (GEN1029 1.0 mg/kg)"},{"description":"Participants received 2.0 mg/kg of GEN1029 Q2W until the end of treatment.","id":"OG004","title":"Biweekly Regimen (GEN1029 2.0 mg/kg)"},{"description":"Participants received 3.0 mg/kg of GEN1029 Q2W until the end of treatment.","id":"OG005","title":"Biweekly Regimen (GEN1029 3.0 mg/kg)"}],"paramType":"MEDIAN","populationDescription":"Full analysis set included all participants who received at least one dose of GEN1029 and were analyzed according to the actual trial treatment received.","reportingStatus":"POSTED","timeFrame":"From Day 1 through 8.8 months (corresponding to maximum observed duration)","title":"Overall Survival (OS) According to RECIST 1.1","type":"SECONDARY","unitOfMeasure":"months"}